Overview of human obesity and central mechanisms regulating energy homeostasis

Annals of Clinical Biochemistry

Volumn 45, Issue 3, 2008, Pages 245-255

  Crowley, Vivion E F ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; INSULIN; LEPTIN; MELANOCORTIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL PAIN; APPETITE; BARIATRIC SURGERY; BLOATING; CALORIC INTAKE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; CLINICAL LABORATORY; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; ENERGY BALANCE; FLATULENCE; FOOD INTAKE; GENETIC ANALYSIS; HEADACHE; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; INSOMNIA; MEDICAL RESEARCH; MENTAL DISEASE; METABOLIC SYNDROME X; METABOLISM; NAUSEA; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SATIETY; WORKLOAD; XEROSTOMIA;

APPETITE; ENERGY INTAKE; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; HYPOTHALAMUS; INSULIN; LEPTIN; MELANOCORTINS; MODELS, BIOLOGICAL; OBESITY; SATIATION;

MAMMALIA;

EID: 44249094622     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2007.007193     Document Type: Review

References (102)

1. Flegal KM, Carrol MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7
2. Molarius A, Seidell JC, Kuulasmaa K, et al. Education levels, relative body weight and changes in their association over 10 years: an international perspective from the WHO MONICA Project. J Epidemiol Commun Health 2000;51:1260-8
3. World Health Organization. Controlling the Global Obesity Epidemic. See http://www.who.int/nut/obs.htm (2003)
4. Chan MJ, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961-9
5. McMillan DC, Sattar N, McArdle CS. ABC of obesity: obesity and cancer. BMJ 2006;333:1109-11
6. Scottish Intercollegiate Guidelines Network. Management of Obesity in Children and Young Adults. A National Clinical Guideline. Edinburgh: Royal College of Physicians, 2003:1-23
7. Department of Health and Children. Obesity - The Policy Challenges. The Report of the National Taskforce on Obesity. Ireland: Department of Health and Children, 2005
8. WHO Expert Committee. Physical Status: the Use and Interpretation of Anthropometry. WHO Technical Report Series no. 854. Geneva: WHO, 1995
9. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-43
10. Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. Br Med Bull 1997;53:238-52
11. Jebb S, Wells J. Measuring body composition in adults and children. In: Kopelman PG, Caterson ID, Dietz WH, eds. Clinical Obesity in Adults and Children. 2nd edn. Oxford: Blackwell Publishing, 2005:12-28
12. Weiss R, Caprio S. The metabolic consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab 2005;19:405-19
13. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centres for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Centre for Health Statistics version. Paediatrics 2002;109:45-60
14. WHO. The World Health Report 1998. Life in the 21st Century - A Vision for All. Geneva: WHO, 1998
15. Seidell JC, Rissanen AM. Prevalence of obesity in adults. The global epidemic. In: Gray GA, Bouchard C, eds. Handbook of Obesity: Etiology and Pathophysiology. 2nd edn. New York: Marcel Dekker, 2004:93-107
16. Egger G, Swinburn B. An ecological approach to the obesity pandemic. BMJ 1997;315:477-80
17. Stunkard AJ, Sorensen TI, Hanis C, et al. An adoption study of human obesity. N Engl J Med 1986;314:193-8
18. Rice T, Perusse L, Bouchard C, Rao DC. Familial aggregation of body mass index and subcutaneous fat measures in the longitudinal Quebec family study. Genet Epidemiol 1999;16:316-34
19. Kopelman PG. Investigation of obesity. Clin Endocrinol 1994;41:703-8
20. Farooqi IS, O'Rahilly S. Monogenic obesity in humans. Ann Rev Med 2005;56:443-58
21. Leibel RL. Obesity. N Engl J Med 1997;337:396-407
22. Hetherington AW, Ranson SW. Hypothalamic lesions and adiposity in the rat. Anat Rec 1940;78:149-72
23. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse Obese gene and its human homologue. Nature 1994;372:425-32
24. Leibel RL, Chung WK, Chua SC. The molecular genetics of rodent single gene obesities. J Biol Chem 1997;272:31937-40
25. Bultman SJ, Michaud EL, Woychik RP. Molecular characterization of the mouse Agouti locus. Cell 1992;71:1195-204
26. fat mice. Cell 1997;88:73-8
27. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997;88:131-41
28. Yaswen L, Diehl N, Brennan MB, Hoggeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999;5:1066-70
29. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903-8
30. Clement K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;392:398-401
31. Jackson RS, Creemers JW, Ohagi S, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997;16:303-6
32. Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155-7
33. Yeo GS, Farooqi IS, Aminian S, et al. A frameshift in MC4R associated with dominantly inherited human obesity. Nat Genet 1998;20:111-12
34. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000;62:413-37
35. Bates SH, Myers MG Jr. The role of leptin recetor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab 2003;14:447- 52
36. Elmquist JK. Unraveling the CNS pathways underlying responses to leptin. Nat Neurosci 1998;1:445-50
37. Schwartz MW, Woods SC, Porte D Jr, Seely RJ, Baskin DG. Central nervous system control of food intake. Nature 2000;404:661-71
38. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-50
39. Qu D, Ludwig DS, Gammeltoft S. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996;380:243-7
40. Clark JT, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behaviour in rats. Endocrinology 1984;115:427-9
41. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996;274:1704-7
42. Cone RD. The central melanocortin system and energy homeostasis. Trends Endocrinol Metab 1999;10:211-16
43. Yeo GS, Farooqi IS, Challis BG, Jackson RS, O'Rahilly S. The role of melanocortin signaling in the control of body weight: evidence from human and murine genetic models. Q J Med 2000;93:7-14
44. Thornton JE, Cheung CC, Clifton DK, Steiner RA. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 1997;138:5063-16
45. Bertagna X. Proopiomelanocortin-derived peptides. Endcorinol Metab Clin North Am 1994;23:467-85
46. Gantz I, Konda Y, Tashiro T, et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246-50
47. Gantz I, Miwa H, Konda Y, et al. Molecular cloning, expression and gene localization of a fourth melanocortin receptor. J Biol Chem 1993;268:15174-9
48. Crowley VEF, Yeo GS. Obesity therapy: altering the energy intake and expenditure balance sheet. Nat Drug Disc Rev 2002;1:276-86
49. Yang Y, Chen M, Lai Y, et al. Molecular determinants of human melanocortin-4-receptor responsible for SHU9119 selective activity. J Biol Chem 2002;277:2032-5
50. Vaisse C, Clement K, Durand E, et al. Melanocortin-4-receptor mutations are a frequent and heterogenous cause of morbid obesity. J Clin Invest 2000;106:253-62
51. Hinney A, Schmidt A, Nottebom K, et al. Several mutations in the melanocortin-4-receptor gene including a nonsense and frameshift mutation associated with a dominantly inherited obesity in humans. J Clin Endocrinol Metab 1999;84:1483-6
52. Rau H, Reaves BJ, O'Rahilly S, Whitehead JP. Truncated human leptin (delta 133) associated with extreme obesity undergoes proteasomal degradation after defective intracellular transport. Endocrinology 1999;140:1718-23
53. Strobel A, Issad T, Camion L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998;18:213-15
54. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;34:879-84
55. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyperresponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110:1093-103
56. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999;84:3686-95
57. Halaas JL, Boozer C, Blair-West J, et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997;94:8878-83
58. Harris M, Aschkenasai C, Elias CF, et al. Transcriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling. J Clin Invest 2001;107:111-20
59. Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007;356:237-47
60. Lee YS, Challis BG, Thompson DA, et al. A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. Cell Metab 2006;3:135-40
61. Jackson RS, Creemers JW, Farooqi IS, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 2003;112:1550-60
62. Jacobson P, Ukkola O, Rankinen T, et al. Melanocortin 4 receptor sequence variations are seldom a cause of human obesity: the Swedish Obese Subjects, the HERITAGE Family Study and a Memphis cohort. J Clin Endocrinol Metab 2002;87:4442-6
63. Dempfle A, Hinney A, Heinzel-Gutenbrunner M, et al. Large quantitative effect on melanocortin-4 receptor gene mutations on body mass index. J Med Genet 2005;41:795-800
64. Alharbi KK, Spanakis E, Tan K, et al. Prevalence and functionality of paucimorphic and private MC4R mutations in a large, unselected European British population, scanned by meltMADGE. Hum Mutat 2007;28:294- 302
65. Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:1085-95
66. Cosnidine RV, Caro JF. Leptin in humans: current progress and future directions. Clin Chem 1996;42:843-4
67. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-75
68. Kievit P, Howard JK, Badman MK, et al. Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC expressing cells. Cell Metab 2006;4:123-32
69. McMinn JE, Baskin DG, Schwartz MW. Neuroendocrine mechanisms regulating food intake and body weight. Obes Rev 2000;1:37-46
70. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-5
71. Yeo GS, Connie Hung CC, Rochford J, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004;7:1187-9
72. Woods SC, Benoit SC, Clegg DJ, Seeley RJ. Clinical endocrinology and metabolism. Regulation of energy homeostasis by peripheral signals. Best Pract Res Clin Endocrinol Metab 2004;18:497-515
73. Small CJ, Bloom SR. Gut hormones and the control of appetite. Trends Endocrinol Metab 2004;15:259-63
74. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973;84:488-95
75. Ballinger A, McLoughlin L, Medbak S, Clark M. Cholecystokinin is a satiety hormone in humans at physiological post-prandial plasma concentrations. Clin Sci (Lond) 1995;89:375-81
76. Wynne K, Stanley S, Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab 2004;89:2576-82
77. Moran TH. Cholecystokinin and satiety: current perspectives. Nutrition 2000;16:858-65
78. Holst JJ. Enteroglucagon. Annu Rev Physiol 1997;59:257-71
79. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the regulation of feeding. Nature 1996;379:66-72
80. Bray GA. Afferent signals regulating food intake. Proc Nutr Soc 2000;59:373-84
81. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endcrinol Metab 2005;1:22-31
82. Pedersen-Bjergaard U, Host U, Kelbaek H, et al. Influence of meal composition on postprandial peripheral concentrations of vasoactive peptides in man. Scand J Clin Lab Invest 1996;56:497-503
83. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-4
84. Challis BG, Pinnock SB, Coll AP, et al. Acute effects of PYY(3-36) on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Comm 2003;311:915-19
85. Adams SH, Won WB, Schonhoff SE, Leiter AB, Patreniti JR. Effects of peptide YY(3-36) on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology 2004;145:4967-75
86. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941-8
87. Murphy KG, Dhillo WS, Bloom SR. Gut peptides in the regulation of food intake and energy homeostasis. Endocr Rev 2006;27:719-27
88. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endcorinology 2001;142:4244-50
89. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003;88:4696-701
90. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from the stomach. Nature 1999;402:656-60
91. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001;50:2540-7
92. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992
93. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003;138:389-96
94. Korner J, Bessler M, Cirilo CJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY and insulin. J Clin Endocrinol Metab 2005;90:359-65
95. Labib M. The investigation and management of obesity. J Clin Path 2003;56:17-25
96. National Institute for Health and Clinical Excellence (NICE). NICE Clinical Guideline 43: Obesity - guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children London: NICE, December 2006
97. Pinkney J. Obesity and disease: hormones and obesity. In: Kopelman PG, Caterson ID, Dietz WH, eds. Clinical Obesity in Adults and Children. 2nd edn. Oxford: Blackwell Publishing, 2005:198-212
98. Farooqi IS. The severly obese patient-agentic work-up. Nat Clin Pract Endocrinol Metab 2006;2:172-7
99. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 2007;369:71-7
100. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from RIO-Europe study. Lancet 2005;365:1389-97
101. Curioni C, Andre C. Rimonabant for overweight or obesity Cochrane Database Syst Rev 2006, Oct 18(4):CD006162
102. Aronne LJ. Is rimonabant a safe and effective treatment for obesity? Nat Clin Pract Endocrinol Metab 2007;3:388-9